Navigation Links
Aptium Oncology Names New Chief Operating Officer
Date:6/8/2009

Paul O'Dea, VP and Executive Director of Cedars-Sinai Outpatient Cancer Center Appointed COO

LOS ANGELES, June 8 /PRNewswire-USNewswire/ -- Aptium Oncology today announced the appointment of Paul R. O'Dea to the position of Chief Operating Officer (COO). O'Dea was formerly Vice President, Aptium Oncology and Executive Director, Cedars-Sinai Outpatient Cancer Center, part of the Aptium network of hospital-based cancer centers. The appointment was effective June 1, 2009.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090608/DC28167)

"Paul has consistently distinguished himself throughout his 20-year career with Aptium Oncology," says Peter Jessup, Chief Executive Officer, Aptium Oncology. "His leadership abilities, combined with his extensive knowledge and keenly strategic insights into our operations will be a tremendous asset that stand him in good stead for this position. I'm confident that Aptium's commitment to advancing comprehensive cancer services and patient care of the highest quality will continue to thrive with Paul as our COO."

O'Dea joined Aptium Oncology in 1989 as Pharmacy Director of Cedars-Sinai Outpatient Cancer Center (CSOCC) at the Samuel Oschin Comprehensive Cancer Institute in Los Angeles, California. He was appointed the Center's Associate Executive Director of Operations in 1996, and promoted to Executive Director of Operations in 1997.

"I appreciate the many opportunities provided to me throughout my career with Aptium Oncology and look forward to bringing that experience to the COO position through operational excellence, enhanced patient care and business value," says O'Dea. "With its innovative offering of comprehensive patient care services, ongoing process improvements and new programs, Aptium is well positioned to help achieve better lives for cancer patients and their families."

Prior to joining Aptium Oncology, O'Dea held pharmacy positions with several prestigious health care institutions including nine years with the University of California, Los Angeles (UCLA). He received his Bachelor of Science in Pharmacy from the University of Connecticut in 1969. O'Dea has published and presented extensively. He is also a member of numerous professional organizations including the California Society of Health Systems Pharmacists, American Society of Health Systems Pharmacists, Health Care Executives of Southern California and the American College of Healthcare Executives, the Association of Cancer Executives, and a delegate member of the Association of Community Cancer Centers.

About Aptium Oncology

Aptium Oncology has 25 years of experience managing outpatient oncology services at leading medical institutions throughout the United States. Aptium Oncology is a pioneer in designing, building and managing comprehensive cancer centers with a steadfast vision to transform cancer care environments by bringing every necessary service to one central place. The intent of this single place is to help patients achieve longer, better lives. Aptium Oncology's corporate headquarters is located in Los Angeles, California. For more information, visit www.aptiumoncology.com.


'/>"/>
SOURCE Aptium Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... S.S. Nesbitt as the latest addition to its growing list of Partner Firms. ... throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing the ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... Florida (PRWEB) , ... February 10, 2016 , ... ... Club) announced that it has been awarded the prestigious Distinguished Emerald Club of ... award program conducted by BoardRoom magazine, one of the most respected trade publications ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Workrite Ergonomics ... most versatile series of monitor mounts ever. , “Our goal was to develop ... easy to install system that we have ever created.” said Darren Hulsey, Product Manager ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, ... Monday night, Feb. 8, prior to the evening session of the university’s 80th Annual ... GO! Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 --> --> ... Japan .  --> Japan .  --> A ... With submission, Shire continues to strengthen ... With submission, Shire continues to strengthen its presence ... submission, Shire continues to strengthen its presence ...
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology: